null
US
Sign In
Sign Up for Free
Sign Up
We have detected that Javascript is not enabled in your browser. The dynamic nature of our site means that Javascript must be enabled to function properly. Please read our
terms and conditions
for more information.
Next up
Copy and Edit
You need to log in to complete this action!
Register for Free
62944
Parkinson's Disease
Description
Pham1056 Mind Map on Parkinson's Disease, created by Affy MD on 30/04/2013.
No tags specified
pham1056
pham1056
Mind Map by
Affy MD
, updated more than 1 year ago
More
Less
Created by
Affy MD
over 11 years ago
56
1
0
Resource summary
Parkinson's Disease
Excitotoxicity
Calcium OVERLOAD
Neuronal Death: Associated with Ca++ overload of cells and membrane damage
Glutamate activates: - NMDA. - AMPA, - Metabotropic receptors
Epidemology
More Males are affected
Age of onset >50 years old
Possible Trigger Factors
Toxins
(MPTP) •Contaminant in heroin substitute led to "frozen addict‟ syndrome •induces parkinsonism – similar to some herbicides
Infection
Encephalitis lethargica
Genetic
Not usually familial
Enviromental
Dopamine oxidation
MPTP
Rotenone (herbicide)
Dopamine (DA) pathways
Due to: •Dopaminergic depletion in basal ganglia (nigro-striatal pathway) •Leading to a relative excess of acetylcholine in striatum
Nigrostraital – motor
Lack of DA or inhibition of dopaminergic neurones may lead to parkinsonism
Inhibits release of acetylcholine (ACh) from striatum
Mesolimbic & mesocortical – thought
Excessive DA or overactive dopaminergic neurones may lead to psychosis
Tuberohypophyseal – hypothalamus/pituitary
Prolactin release from pituitary gland - inhibited by dopamine
Chemoreceptor trigger zone - vomiting reflex
Dopaminergic stimulation leads to vomiting
Metabolism of dopamine
Dopamine eventually metabolised to Homovanillic acid
Metabolic Pathways
Catechol-o-methyltransferase
Monoamine oxidase
Aldehyde dehydrogenase
Symptoms
TREMOR
Rigidity
COGWHEEL
Bradykinesia
Akinesia
'Pill rolling'
Gait & Posture
Shuffling
Stooping
Speech
Montone
Early Stages: Levodopa, Dopamine Agonists, MAO-B-I
Treatment
Dopamine Precursors
Levodopa
Short Half-Life = 2 hours
May enhance DA in Limbic System
S.E. N+V, Cardiovascular - Hypotension
Treat with Domperidone, does NOT cross BBB
Psychological effects – delusions and hallucinations, but more commonly (20%) confusion, disorientation, insomnia or nightmares. Daytime drowsiness
Dyskinesia
Within 2 years of taking L-Dopa
Involuntary writhing movements
Motor Fluctuations ('On-off' effect)
Dopa-decarboxylase inhibitor can be added
Increases: Life expectancy. Improves: motor function, quality of life.
Some symptoms not improved – e.g. dysphagia, cognitive decline
MOA: Precursor of DA
Dopa Decarboxylase Inhibitors
Benserazide
Can be combined with L-Dopa to make Co-beneldopa (Madopar)
Carbidopa
Can be combined with L-Dopa to make Co-Careldopa (Sinemet)
Intestinal Gel - Duodopa, for late stage PD
Directly into Duodenum
Requires electronic pump device
Dose
The total morning dose is usually 5-10 ml, corresponding to 100-200 mg levodopa. (should not exceed 15 ml (300 mg levodopa)
MOA: Inhibit the breakdown of L-Dopa to DA
Monoamine Oxidase B Inhibitors
DRUGS
Selegilene
Better with Levodopa than alone
Rasagilene
Neuroprotective properties
Protect DA from intraneuronal breakdown
Catechol-O-Methyltransferase Inhibitors
DRUGS
Entacapone
Combo: Levodopa, Carbidopa & Entacopone - STALEVO
Tolcapone
MOA: Inhibits breakdown of peripheral l-dopa by COMT to increase levodopa level and enhance effect. May be able to reduce levodopa dose by 10-30%
Amantadine
MOA: Increase DA release inhibit amine uptake, direct action on DA receptors
Limited by SE & worsening on withdrawal
Anti-viral drug
Dopamine Receptor Agonists
Ergot-Derived (Fibrotic Reactions)
Drugs
Bromocriptine
Cabergoline
Lisuride
Pergolide
Increase risk of pulmonary, retroperitoneal and cardiac fibrosis
Non-Ergot Derived
Pramipexole
Ropinirole
Apomorphine
D1 & D2 Agonist
SC or Infusion
Initiation - Hospital
Discharge: Monitor, adjust dose
Side Effects
Nausea, vomiting, drowsiness, hallucinations, injection site nodules, < commonly postural hypotension, breathing difficulties, dyskinesias, anaemia
Expensive
Increase sleepiness
Side Effects
Nausea/vomiting
Postural hypotension
Hallucinations
Confusion
Dyskinesias
Reckless Behaviour /Gambling
Antimuscarinic Drugs
DRUGS
Procyclidine
Orphenadrine
Artane
Benzatropine
Ach: excitatory effect on striatal neurones. Also exerts presynaptic inhibitory effect on dopaminergic nerve terminals
Treat tremor effectively
SIDE EFFECTS
dry mouth, urinary retention, visual disturbances, constipation - euphoria, drowsiness, confusion, hallucinations, cognitive impairment
Later Stages: Dopamine Agonists, COMT-I, MAO-B-I
2nd Choice: Amantadine, Apomorphine
All must be used as adjunctive therapy
Show full summary
Hide full summary
Want to create your own
Mind Maps
for
free
with GoConqr?
Learn more
.
Similar
Diabetes - Type 2
Affy MD
Cell & Gene Replacement Therapy
Zita Wormuth
Genome and medicine
ingramsarah
affective disorders
Karo
Epilepsy
Affy MD
sleep
Karo
Diabetes
Karo
Diabetes
Ahmed salah
AQA GCSE Physics Unit 2
Gabi Germain
3.1 Keywords - Marketing
Mr_Lambert_Hungerhil
1PR101 2.test - Část 17.
Nikola Truong
Browse Library